Sadakatsu Ikeda
Overview
Explore the profile of Sadakatsu Ikeda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
2308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Uehara Y, Izumi H, Kobayashi I, Matsumoto S, Hosomi Y, Okuno T, et al.
Lung Cancer
. 2025 Mar;
202:108479.
PMID: 40088581
Background: EGFR exon 19 insertions (EGFRex19ins) are rare EGFR mutations. Their clinical-genomic characteristics and outcomes with EGFR-tyrosine kinase inhibitors (TKIs) remain uncertain. Methods: We evaluated the clinical-genomic characteristics and outcomes...
2.
El-Deiry W, Bresson C, Wunder F, Carneiro B, Dizon D, Warner J, et al.
Oncotarget
. 2025 Mar;
16:140-162.
PMID: 40073368
The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed...
3.
Noji R, Tohyama K, Nakamura S, Naito T, Oikawa Y, Kuroshima T, et al.
Int J Mol Sci
. 2025 Jan;
26(1.
PMID: 39796090
Immune checkpoint inhibitors (ICIs) are effective in treating recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), but only 20% of patients achieve durable responses. This study evaluated circulating tumor DNA...
4.
Morikawa R, Nitta K, Yasuda S, Kano Y, Noji R, Aoyama S, et al.
Expert Opin Drug Saf
. 2024 Dec;
:1-8.
PMID: 39688366
Background: Gastrointestinal (GI) toxicities are among the most common and potentially severe immune-related adverse events (irAEs), and data on risk factors remain limited. This study aimed to identify risk factors...
5.
Tanaka H, Yoshida S, Aoyama S, Ikeda S, Kunieda J, Ohashi K, et al.
IJU Case Rep
. 2024 Sep;
7(5):395-398.
PMID: 39224671
Introduction: Double-negative prostate cancer, an androgen receptor-independent prostate cancer without features of neuroendocrine tumors, is refractory to treatment but could be an ideal candidate for individualized treatment. Case Presentation: An...
6.
Kobayashi H, Otsuki A, Ikeda S, Nakashima K, Oyama Y
Cureus
. 2024 Aug;
16(8):e67307.
PMID: 39165617
Introduction: Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) combination therapy has a potential efficacy in a specific subset of non-squamous non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor...
7.
Kobayashi H, Oyama Y, Ikeda S
Cureus
. 2024 Aug;
16(7):e65795.
PMID: 39114207
Background: The simplified Pulmonary Embolism Severity Index (sPESI) has limitations when evaluating acute pulmonary embolism (PE) in patients with concurrent malignancy. Despite its utility in predicting outcomes among cancer patients,...
8.
Yasui S, Honda T, Onishi I, Ikeda S, Miyazaki Y
Cureus
. 2024 Mar;
16(2):e54739.
PMID: 38523924
The serine-threonine protein kinase B-RAF (BRAF) fusions are rarely observed in non-small cell lung cancer (NSCLC) accounting for less than 1%, and therapeutic evidence for molecular-targeted drugs is lacking, unlike...
9.
Kumaki Y, Oda G, Ikeda S
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760522
The gene plays a vital role in cellular proliferation, earning it recognition as a principal oncogene. Therapies that target amplification have demonstrated promising results both in preclinical models and in...
10.
Matsubara J, Mukai K, Kondo T, Yoshioka M, Kage H, Oda K, et al.
JAMA Netw Open
. 2023 Jul;
6(7):e2323336.
PMID: 37459099
Importance: Precision oncology using comprehensive genomic profiling (CGP) by next-generation sequencing is aimed at companion diagnosis and genomic profiling. The clinical utility of CGP before the standard of care (SOC)...